Immunology Strategic Roundup: Rising Evidence Standards | Sep 22—Oct 26, 2026
Immunology market trends reveal rising evidence standards as psoriasis…
Samsung Bioepis and Teva Expand SB41 and SB44 Biosimilar Partnership | Lucid Diligence Brief
This Lucid Diligence Brief explores Samsung Bioepis’ expansion of its…
EADV 2026 Preview: Emerging Dermatology Therapies and Competitive Trends
EADV 2026 at a glance At 2026,will differentiation in dermatology move beyond…
AbbVie–Iambic AI Drug Discovery Collaboration: Strategic Implications | Lucid Diligence Brief
This Lucid Diligence Brief examines the AbbVie–Iambic AI drug discovery…
Harbour BioMed and Sinopharm Innovation Consortium Expands Biologics Strategy | Lucid Diligence Brief
Harbour BioMed partners with Sinopharm to establish an innovation consortium…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Vaccines Today—May 22, 2026
This weekly update covers recent developments in vaccine research, including…
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics Professional…
Public Health Today—May 1, 2026
This is a weekly update in public health, highlighting advances across clinical…
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor…
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…